Vyvanse, a prescription medication commonly used to treat ADHD, has recently experienced a significant shortage in New York City, with some pharmacies reporting delays of up to two weeks. This shortage has left many patients without their necessary medication for several days, impacting their daily functioning and overall mental health. The shortage is attributed to increased demand, supply chain disruptions, and stockpiling behaviors, particularly by individuals who may accumulate more than their prescribed amounts. Such hoarding exacerbates the scarcity, leading to further difficulties for those genuinely reliant on the drug for managing their symptoms. Patients facing this shortage are encouraged to communicate closely with healthcare providers to explore alternative treatment plans or adjustments in medication schedules. Pharmacists and medical professionals are also working to distribute available supplies more equitably and seeking solutions such as prioritizing patients with acute needs. Furthermore, community awareness about responsible medication use and discouraging hoarding practices is essential. Educating patients on the broader consequences of stockpiling ADHD medications helps promote fairness and accessibility. For long-term resolution, collaborations between pharmaceutical manufacturers, distributors, healthcare providers, and regulatory bodies are needed to enhance supply stability and prevent future shortages. Meanwhile, patients are advised to stay informed through official channels and report shortages to healthcare authorities to assist in monitoring and managing the situation. Understanding the Vyvanse shortage context and encouraging responsible practices could help mitigate the crisis effects, improving access for those who depend on the medication to function effectively in their daily lives.